Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Hsien-Hsueh Shih, MD,1,* Chi-Yung Shang, MD, PhD,1,2,* and Susan Shur-Fen Gau, MD, PhD1–3
Abstract
Objective: Methylphenidate and atomoxetine are efficacious in reducing core symptoms of attention-deficit/hyperactivity
disorder (ADHD), but little is known about their efficacy in improving emotional/behavioral problems among youths with
ADHD.
Methods: One hundred sixty drug-naı̈ve youths with DSM-IV-defined ADHD, aged 7–16 years, were recruited and randomly
assigned to osmotic-release oral system methylphenidate (OROS-methylphenidate; n = 80) and atomoxetine (n = 80) in a 24-
week, open-label, head-to-head clinical trial. The primary efficacy measure was parent-reported Child Behavior Checklist
(CBCL), and the secondary efficacy measures included Youth Self Report (YSR) and Strengths and Difficulties Ques-
tionnaire (SDQ), which was based on the ratings of parents, teachers, and subjects.
Results: For CBCL, both methylphenidate and atomoxetine groups showed significant improvement in all scores at weeks 8
and 24 except Somatic Complaints in the atomoxetine group. For SDQ, both treatment groups showed significant im-
provements in the Hyperactive and Conduct subscales for parent ratings, and the Externalizing subscale for teacher ratings at
week 24. Methylphenidate was associated with greater improvements in Aggressive Behavior and Somatic Complaints of
CBCL and in Conduct subscale of self-reported SDQ at week 24 compared with atomoxetine.
Conclusions: Our findings provide evidence to support that both methylphenidate and atomoxetine were effective in im-
proving a wide range of emotional/behavioral problems in youths with ADHD after 24 weeks of treatment, with greater
improvement in aggressive behavior, somatic complaints, and conduct problems in the methylphenidate group.
1
Department of Psychiatry, National Taiwan University Hospital, Taipei, Taiwan.
2
Department of Psychiatry, College of Medicine, National Taiwan University, Taipei, Taiwan.
3
Department of Psychology, Graduate Institute of Brain and Mind Sciences, Institute of Clinical Medicine, National Taiwan University, Taipei,
Taiwan.
*These authors contributed equally to this work as the first authors.
Funding: This study was supported by the grant from the National Science Council (NSC 98-2314-B-002-051-MY3, NSC99-2627-B-002-015,
NSC100-2627-B-002-014) and the National Health Research Institute (NHRI-EX100-10008PI, NHRI-EX101-10008PI, NHRI-EX106-10404PI), Taiwan.
1
2 SHIH ET AL.
dopamine and noradrenaline reuptake inhibitor, promotes the re- (K-SADSE) (Gau et al. 2005). We excluded participants who had
lease of stored dopamine from presynaptic vesicles (Volkow et al. comorbid conditions with bipolar disorders, psychosis, any sub-
2005) and is recognized as the first-line treatment for ADHD for stance abuse, autism spectrum disorders, intellectual disability
decades worldwide. Atomoxetine is a highly specific inhibitor of (Full-Scale Intelligence Quotient score <80), or had serious medi-
presynaptic norepinephrine transporter, with little affinity for other cal conditions such as cardiovascular disease, history of seizure, or
neurotransmitter transporters or receptors (Garnock-Jones and prior electroencephalogram abnormalities related to epilepsy, or
Keating 2009). Clinical trials have shown that both methylpheni- had ever used any psychotropic medications before the study. The
date and atomoxetine treatments are associated with clinically details have been reported elsewhere (Shang et al. 2015).
meaningful and comparable effectiveness in improving the core
symptoms of ADHD across situations (Kratochvil et al. 2002; Study design and procedures
Shang et al. 2015). In contrast, results for the effectiveness of
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
(Goodman 1999). Each item is rated on a three-point Likert scale tween week 24 (last observation) and baseline, with the small,
(0 = not true, 1 = somewhat true, and 2 = certainly true). There are medium, and large effect sizes being d = 0.2 to <0.5, >0.5 to <0.8,
three versions of the SDQ for ratings by self, parents, and teachers. and >0.8, respectively. In particular, both intercepts and slope
Our previous work on the Chinese version of SDQ identified four (time) effects in the linear mixed model with time-dependent var-
subscales in the parent version (prosocial, conduct, internalizing, iables were treated as random effects, to account for variations
and hyperactive), four subscales in the teacher version (peer/pro- among subjects in baseline values, and slopes for individual tra-
social, externalizing, internalizing, and inattention), and five sub- jectories of changes in emotional/behavioral problems over visits,
scales in the self-report (prosocial, conduct, hyperactive, peer in addition to the main treatment and fixed time effects of the two
problems, and emotion) (Liu et al. 2013). treatment groups. To test the difference in the slope of change
between the two treatment groups, the interaction terms between
Statistical analyses visits · drugs were tested. The alpha value was preselected at the
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
Completed CBCL (n=76) and YSR (n=51) at baseline Completed CBCL (n=80) and YSR (n=54) at
Completed CBCL (n=60) and YSR (n=38) at week 8 Completed CBCL (n=68) and YSR (n=45) at week
Completed CBCL (n=37) and YSR (n=22) at week 24 Completed CBCL (n=36) and YSR (n=25) at week 24
FIG. 1. Flowchart of the randomization procedure. CBCL, Child Behavior Checklist; YSR, Youth Self Report.
4 SHIH ET AL.
the methylphenidate group had higher Peer/Prosocial scores of day at week 8 (visit 4), 31.39 (SD = 9.12) mg/day or 0.93
teacher-reported SDQ compared with the atomoxetine group (SD = 0.31) mg/kg per day at week 12 (visit 5), 31.68 (SD = 8.76)
(Table 1). mg/day or 0.95 (SD = 0.31) mg/kg per day at week 16 (visit 6), and
For the OROS-methylphenidate group, the mean administered 31.74 (SD = 10.34) mg/day or 0.98 (SD = 0.28) mg/kg per day at
dose was 20.45 (SD = 6.76) mg/day or 0.64 (SD = 0.19) mg/kg per week 24 (visit 7). Regarding adverse events, vomiting ( p = 0.017),
day at week 2 (visit 2), 24.91 (SD = 9.65) mg/day or 0.75 somnolence ( p < 0.001), and dizziness ( p = 0.009) were reported
(SD = 0.24) mg/kg per day at week 4 (visit 3), 26.38 (SD = 11.32) more often for atomoxetine, while insomnia ( p = 0.035) was re-
mg/day or 0.79 (SD = 0.28) mg/kg per day at week 8 (visit 4), 27.98 ported more often for OROS-methylphenidate. The details have
(SD = 11.77) mg/day or 0.84 (SD = 0.3) mg/kg per day at week 12 been reported elsewhere (Shang et al. 2015).
(visit 5), 27.02 (SD = 11.83) mg/day or 0.81 (SD = 0.32) mg/kg per
day at week 16 (visit 6), and 27.83 (SD = 12.44) mg/day or 0.82
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
(SD = 0.34) mg/kg per day at week 24 (visit 7). For the atomoxetine Efficacy on CBCL
group, the mean administered dose was 26.09 (SD = 9.07) mg/day Both treatment groups showed significant improvements in all
or 0.78 (SD = 0.28) mg/kg per day at week 2 (visit 2), 27.94 the eight scales of CBCL from baseline to week 8 and from baseline
(SD = 9.74) mg/day or 0.84 (SD = 0.33) mg/kg per day at week 4 to week 24 except Somatic Complaints in the atomoxetine group
(visit 3), 29.37 (SD = 8.23) mg/day or 0.89 (SD = 0.31) mg/kg per (Table 2). Compared with the atomoxetine group (Table 2), the
Table 1. Demographics and Baseline Emotional/Behavioral (t-Score) Between the Two Treatment Groups
Methylphenidate
Mean (SD) or n (%) Atomoxetine (n = 80) (n = 76) F/v2 p value
CBCL, Child Behavior Checklist; YSR, Youth Self Report; SDQ, Strengths and Difficulties Questionnaire.
*p < 0.05.
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
Table 2. Change in Child Behavior Checklist and Youth Self Report from Baseline to Weeks 8 and 24 (Endpoint) in the Two Treatment Groups
CBCL
Aggressive -2.66 (10.42) -0.24 0.033* -4.46 (11.36) -0.37 0.002** -8.31 (10.28) -0.60 <0.001*** -8.48 (9.86) -0.68 <0.001*** 0.003** 0.032*
behavior
Anxious/ -4.04 (12.72) -0.31 0.011* -5.33 (11.85) -0.44 <0.001*** -5.02 (11.25) -0.36 0.001** -5.71 (12.57) -0.44 <0.001*** 0.647 0.857
depressed
Attention -5.33 (10.02) -0.54 <0.001*** -6.80 (10.61) -0.66 <0.001*** -8.37 (9.84) -0.70 <0.001*** -8.59 (10.30) -0.80 <0.001*** 0.087 0.326
problems
Delinquent -4.01 (8.52) -0.43 <0.001*** -4.93 (8.87) -0.52 <0.001*** -8.74 (11.55) -0.63 <0.001*** -7.98 (11.17) -0.64 <0.001*** 0.009** 0.083
behavior
Social problems -5.72 (10.90) -0.50 <0.001*** -6.39 (9.81) -0.55 <0.001*** -7.11 (9.33) -0.58 <0.001*** -7.57 (10.30) -0.68 <0.001*** 0.443 0.502
Somatic 0.14 (12.99) 0.02 0.898 -0.14 (13.10) -0.01 0.931 -4.20 (11.75) -0.30 0.009** -6.18 (12.95) -0.48 <0.001*** 0.051 0.008**
complaints
Thought -5.22 (12.18) -0.50 <0.001*** -4.51 (12.53) -0.40 0.004** -5.80 (12.85) -0.38 0.001** -6.84 (12.59) -0.52 <0.001*** 0.793 0.287
5
problems
Withdrawn -2.54 (10.21) -0.24 0.039* -2.79 (10.98) -0.25 0.038* -5.78 (10.09) -0.54 <0.001*** -5.81 (11.34) -0.53 <0.001*** 0.073 0.122
YSR
Aggressive -5.60 (14.38) -0.44 0.009** -6.60 (14.42) -0.50 0.003** -7.19 (11.87) -0.40 <0.001*** -9.55 (13.31) -0.55 <0.001*** 0.597 0.338
behavior
Anxious/ -3.55 (15.69) -0.22 0.121 -3.86 (13.57) -0.20 0.066 -6.52 (18.73) -0.34 0.041* -9.59 (17.14) -0.51 0.002** 0.440 0.093
depressed
Attention -6.62 (12.54) -0.51 <0.001*** -9.87 (12.00) -0.74 <0.001*** -9.57 (14.04) -0.74 <0.001*** -13.91 (15.03) -1.00 <0.001*** 0.322 0.177
problems
Delinquent -6.40 (15.67) -0.42 0.009** -6.72 (16.18) -0.41 0.008** -5.23 (17.64) -0.25 0.088 -6.97 (14.19) -0.39 0.005** 0.753 0.941
behavior
Social -5.82 (9.32) -0.48 <0.001*** -6.85 (8.64) -0.55 <0.001*** -4.77 (14.54) -0.38 0.043* -9.43 (12.98) -0.74 <0.001*** 0.694 0.282
problems
Somatic -6.23 (16.55) -0.35 0.016* -7.39 (19.40) -0.42 0.015* -2.31 (19.67) -0.20 0.350 -6.37 (22.25) -0.39 0.061 0.332 0.824
complaints
Thought -2.68 (17.24) -0.20 0.252 -5.41 (16.60) -0.32 0.035* -5.12 (19.85) -0.31 0.093 -8.31 (17.47) -0.46 0.005** 0.555 0.442
problems
Withdrawn 5.58 (14.02) -0.42 0.009** -7.52 (14.05) -0.53 <0.001*** -5.51 (16.75) -0.42 0.039* -6.84 (14.79) -0.50 0.008** 0.985 0.831
*p < 0.05.
**p < 0.01.
***p < 0.001.
A B
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
C D
FIG. 2. Improvements in the emotional/behavioral scores of CBCL in youths with ADHD randomly assigned to treatment with either
methylphenidate or atomoxetine. (A) Aggressive Behavior; (B) Attention Problems; (C) Delinquent Behavior; (D) Social Problems;
(E) Somatic Complaints. For the OROS-methylphenidate group, the mean administered dose was 26.38 (SD = 11.32) mg/day or 0.79
(SD = 0.28) mg/kg per day at visit 4, 27.02 (SD = 11.83) mg/day or 0.81 (SD = 0.32) mg/kg per day at visit 6, and 27.83 (SD = 12.44)
mg/day or 0.82 (SD = 0.34) mg/kg per day at visit 7. For the atomoxetine group, the mean administered dose was 29.37 (SD = 8.23)
mg/day or 0.89 (SD = 0.31) mg/kg per day at visit 4, 31.68 (SD = 8.76) mg/day or 0.95 (SD = 0.31) mg/kg per day at visit 6, and 31.74
(SD = 10.34) mg/day or 0.98 (SD = 0.28) mg/kg per day at visit 7. Error bars indicate 1 SD in both directions. *p < 0.05; d, Cohen’s d.
6
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
Table 3. Change in Strengths and Difficulties Questionnaire from Baseline to Weeks 8 and 24 (Endpoint) in the Two Treatment Groups
Atomoxetine Methylphenidate
Group differences
Week 8-baseline Endpoint-baseline Week 8-baseline Endpoint-baseline
Week 8- Endpoint-
Mean (SD) Cohen’s d p Mean (SD) Cohen’s d p Mean (SD) Cohen’s d p Mean (SD) Cohen’s d p baseline baseline
Parent report
Internalizing -2.19 (9.86) -0.19 0.076 -2.19 (11.63) -0.21 0.122 -3.32 (9.71) -0.32 0.011* -3.23 (9.62) -0.33 0.009** 0.513 0.576
Prosocial 0.49 (9.19) 0.07 0.604 -0.63 (9.66) -0.06 0.593 -0.58 (10.32) -0.07 0.629 0.63 (10.95) 0.06 0.644 0.535 0.482
Hyperactive -1.74 (7.36) -0.28 0.056 -2.42 (6.49) -0.42 0.003** -1.79 (8.33) -0.21 0.179 -1.96 (7.79) -0.32 0.046* 0.968 0.714
Conduct -5.06 (11.96) -0.52 <0.001*** -3.95 (10.56) -0.37 0.003** -8.16 (11.51) -0.71 <0.001*** -7.22 (12.22) -0.67 <0.001*** 0.139 0.099
Self-report
7
Emotion -3.54 (9.26) -0.36 0.015* -3.03 (10.88) -0.30 0.061 -3.99 (9.52) -0.32 0.024* -4.74 (10.08) -0.46 0.004** 0.830 0.446
Prosocial -3.12 (15.55) -0.23 0.184 -3.23 (15.75) -0.24 0.165 0.98 (11.64) 0.06 0.654 0.11 (11.57) 0.01 0.951 0.192 0.262
Hyperactive -2.94 (9.26) -0.43 0.032* -3.22 (9.87) -0.43 0.026* -2.44 (7.54) -0.18 0.156 -2.43 (9.92) -0.28 0.120 0.794 0.707
Conduct -4.30 (10.60) -0.45 0.009** -2.21 (11.09) -0.21 0.174 -4.79 (8.50) -0.34 0.002** -6.95 (10.35) -0.61 <0.001*** 0.821 0.041*
Peer problem -3.38 (9.79) -0.44 0.021* -2.24 (11.84) -0.25 0.201 -1.15 (9.69) -0.09 0.617 -2.42 (10.06) -0.33 0.127 0.307 0.941
Teacher report
Peer/prosocial 3.19 (5.85) 0.30 <0.001*** 2.17 (8.25) 0.25 0.046* 1.62 (6.95) 0.13 0.237 1.37(9.24) 0.15 0.278 0.217 0.623
Externalizing -5.49 (9.49) -0.65 <0.001*** -5.66 (10.64) -0.64 <0.001*** -6.46 (10.53) -0.66 <0.001*** -6.29 (10.41) -0.71 <0.001*** 0.624 0.746
Internalizing -1.38 (9.12) -0.10 0.325 -1.61 (8.69) -0.17 0.157 -1.45 (11.73) -0.11 0.459 -0.17 (10.53) -0.02 0.905 0.970 0.425
Inattention 1.84 (10.58) 0.20 0.235 0.39 (9.52) 0.05 0.754 0.39 (9.21) -0.01 0.672 1.16 (10.81) 0.13 0.432 0.466 0.687
*p < 0.05.
**p < 0.01.
***p < 0.001.
8 SHIH ET AL.
methylphenidate group had greater improvements in Aggressive associated with ADHD, including aggressive, oppositional, and
Behavior ( p = 0.003) and Delinquent Behavior ( p = 0.009) from conduct problems. Meta-analytic reviews in assessing the impact of
baseline to week 8, and in Aggressive Behavior ( p = 0.032) and methylphenidate (Connor et al. 2002) reported a weighted mean ef-
Somatic Complaints ( p = 0.008) from baseline to week 24. In ad- fect size of 0.84 for overt and 0.69 for covert aggression-related
dition, the methylphenidate group had lower scores in Attention behaviors in ADHD, consistent with our findings in the Aggressive
Problems (Fig. 2B) at week 8 (Cohen’s d = 0.35) and week 16 Behavior subscale of CBCL for methylphenidate (Cohen’s d = 0.6 at
(Cohen’s d = 0.55), and Social Problems (Fig. 2D) at week 16 week 8 and 0.68 at week 24). In contrast, although atomoxetine is
(Cohen’s d = 0.57) compared with the atomoxetine group. There effective in reducing the core symptoms of ADHD, a relatively small
were significant effects of the drug · visit interactions on the Ag- effect size of 0.33 was found for disruptive problems (Schwartz and
gressive Behavior ( p = 0.013), Delinquent Behavior ( p = 0.041), Correll 2014), consistent with our findings in the Aggressive Beha-
and Somatic Complaints ( p = 0.003) (Fig. 2A, C, E). There were no vior subscale of CBCL for atomoxetine (Cohen’s d = 0.24 at week 8
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
effects noted for the interactions of drug · visit on the Anxious/- and 0.37 at week 24). A systemic review reported a moderate-to-large
Depressed, Attention Problems, Social Problems, Thought Pro- effect for methylphenidate and a small effect for atomoxetine on
blems, and Withdrawn. oppositional behavior, conduct problems, and aggression in youths
with ADHD (Pringsheim et al. 2015). Animal studies have shown that
Efficacy on YSR aggressive behaviors in mice are associated with the altered function
of dopamine transporter (Yu et al. 2014). Taken together, converging
Both treatment groups showed significant improvements in the evidence supports that methylphenidate demonstrates a greater
YSR scores from baseline to week 8 and from baseline to week 24 magnitude of treatment effect for aggressive spectrum symptoms in
except Anxious/Depressed (weeks 8 and 24) and Thought Problems youths with ADHD compared with atomoxetine. Future studies are
(week 8) in the atomoxetine group, and Delinquent Behavior (week needed to explore the factors associated with the differential effects of
8), Somatic Complaints (weeks 8 and 24), and Thought Problems methylphenidate and atomoxetine on aggression.
(week 8) in the methylphenidate group (Table 2). The analysis of Similarly, our findings demonstrated the effectiveness of both
mean changes in the YSR scores (Table 2) revealed no significant methylphenidate and atomoxetine in improving the externalizing
differences between the two treatment groups from baseline to problems assessed by a parent- and teacher-rated SDQ at week 24,
week 8 and from baseline to week 24. including Hyperactive, Conduct, and Externalizing subscales. No
significant improvement in parent- and self-rated Prosocial subscale
Efficacy on SDQ was observed after 24-week treatment with methylphenidate or
From baseline to week 24, both treatment groups showed sig- atomoxetine, whereas atomoxetine is associated with improvement
nificant improvements in the Hyperactive and Conduct subscales in teacher-rated Peer/Prosocial subscale at weeks 8 and 24. Our
for parent ratings and the Externalizing subscale for teacher ratings previous work has shown the effectiveness of atomoxetine in chil-
(Table 3). For the self-report, the Emotion and Conduct problems dren with ADHD in improving interactions with peers and teachers
improved with methylphenidate treatment at week 24, and the (Shang and Gau 2012). The literature documents the importance of
Hyperactive problems improved with atomoxetine treatment at teacher ratings on treatment response in youths with ADHD (La-
week 24. Compared with the atomoxetine group, the methylphe- vigne et al. 2012), and a lack of reports from teachers may result in
nidate group had greater improvements in the self-reported Con- the inadequate assessment of treatment effects (Miller 1999).
duct subscale ( p = 0.041) at week 24. For internalizing symptoms, our findings showed a similar ef-
ficacy of methylphenidate and atomoxetine in reducing Anxious/-
Depressed symptoms measured by CBCL in youths with ADHD,
Discussion
with effect sizes ranging from 0.31 to 0.44. Previous studies
To our best knowledge, this is the first head-to-head, random- demonstrated the efficacy of atomoxetine on anxiety symptoms
ized, long-term treatment study to prospectively compare the ef- associated with ADHD, with an effect size of 0.4 (Geller et al.
fects of methylphenidate and atomoxetine on a wide range of 2007). In addition, clinical trials showed that symptoms of anxiety
emotional/behavioral problems in drug-naı̈ve youths with ADHD. and depression in patients with ADHD improved after treatment
We found that both treatments are efficacious in reducing the se- with methylphenidate (Mattos et al. 2013).
verity of emotional/behavioral problems measured by CBCL, YSR, The Somatic Complaints subscale of CBCL, one of the inter-
and SDQ. Compared with atomoxetine, methylphenidate is asso- nalizing problems, is intended to assess the physical symptoms with
ciated with greater improvements in Aggressive Behavior and no medical basis, and psychiatric disability may accentuate the
Somatic Complaints of CBCL and in the Conduct subscale of self- incidence of somatic complaints in children with ADHD (Egger
reported SDQ from baseline to week 24. In contrast to an obser- et al. 1999). Previous studies showed that parent-rated somatic
vational study showing no effect of short-acting methylphenidate complaints improved after treatment with methylphenidate (Rap-
on the behavioral problems measured by CBCL in youths with port et al. 2002) in youths with ADHD, consistent with our findings.
ADHD (Wang et al. 2013), our randomized clinical trial using Youths with ADHD experience significant distress at home and in
OROS-methylphenidate once daily provided strong evidence to school, owing to inherent difficulties with this disorder, and may
support that emotional/behavioral problems are reduced by treat- internalize this distress as physical complaint (Rapport et al. 2002).
ment not only with methylphenidate but also with atomoxetine. Further studies are needed to examine whether improved perfor-
Our results showed the large effect of treatment with methylphe- mance at home and in school associated with methylphenidate
nidate in the realm of attention problems (Cohen’s d = 0.7 at week 8 treatment corresponds with reductions in parent-rated somatic
and 0.8 at week 24), consistent with an average effect size of 0.8 in complaints in youths with ADHD.
prior reports (Conners 2002). Previous studies have demonstrated the In our present study, changes in YSR scores also showed sig-
effects of methylphenidate (Conners 2002; Sinzig et al. 2007) and nificant improvements in emotional/behavioral problems from
atomoxetine (Schwartz and Correll 2014) on externalizing symptoms baseline to week 24 for both methylphenidate and atomoxetine,
MEDICATIONS FOR EMOTIONAL/BEHAVIORAL PROBLEMS 9
except the Anxious/Depressed subscale for atomoxetine and the sis/interpretation. H.H.S. and C.Y.S. contributed to drafting the
Somatic Complaints subscale for methylphenidate, inconsistent article, tables, and figures, which were critically reviewed by S.S.G.
with parent ratings of treatment response measured by CBCL. All authors read and approved the final version of the article.
Although youths are valuable informants about their own emo-
tional/behavioral problems (Klimkeit et al. 2006), previous studies Acknowledgment
analyzing ratings on CBCL and YSR showed better parent–youth
agreement for externalizing problems than internalizing problems The authors express thanks to Ming-Fang Chen, M.S., for as-
(Rescorla et al. 2017). For example, youths may report more anx- sistance in data analysis.
ious symptoms with higher degrees of intensity than their parents
(Weitkamp et al. 2010). Parent–youth discrepancies may arise due Disclosures
to not only contextual variations in emotional/behavioral problems
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
Dittmann RW, Schacht A, Helsberg K, Schneider-Fresenius C, Leh- Miller A: Appropriateness of psychostimulant prescription to chil-
mann M, Lehmkuhl G, Wehmeier PM: Atomoxetine versus placebo dren: Theoretical and empirical perspectives. Can J Psychiatry 44:
in children and adolescents with attention-deficit/hyperactivity 1017–1024, 1999.
disorder and comorbid oppositional defiant disorder: A double- Ni HC, Shang CY, Gau SS, Lin YJ, Huang HC, Yang LK: A head-to-
blind, randomized, multicenter trial in Germany. J Child Adolesc head randomized clinical trial of methylphenidate and atomoxetine
Psychopharmacol 21:97–110, 2011. treatment for executive function in adults with attention-deficit
Egger HL, Costello EJ, Erkanli A, Angold A: Somatic complaints and hyperactivity disorder. Int J Neuropsychopharmacol 16:1959–1973,
psychopathology in children and adolescents: Stomach aches, 2013.
musculoskeletal pains, and headaches. J Am Acad Child Adolesc Pringsheim T, Hirsch L, Gardner D, Gorman DA: The pharmaco-
Psychiatry 38:852–860, 1999. logical management of oppositional behaviour, conduct problems,
Faraone SV, Biederman J, Spencer TJ, Aleardi M: Comparing the and aggression in children and adolescents with attention-deficit
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
efficacy of medications for ADHD using meta-analysis. Med- hyperactivity disorder, oppositional defiant disorder, and conduct
GenMed 8:4, 2006. disorder: A systematic review and meta-analysis. Part 1: psychos-
Garnock-Jones KP, Keating GM: Atomoxetine: A review of its use in timulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry 60:
attention-deficit hyperactivity disorder in children and adolescents. 42–51, 2015.
Paediatr Drugs 11:203–226, 2009. Rapport MD, Randall R, Moffitt C: Attention-Deficit/Hyperactivity
Gau SS, Chong MY, Chen TH, Cheng AT: A 3-year panel study of Disorder and methylphenidate: A dose-response analysis and
mental disorders among adolescents in Taiwan. Am J Psychiatry parent-child comparison of somatic complaints. J Atten Disord 6:
162:1344–1350, 2005. 15–24, 2002.
Gelade K, Janssen TW, Bink M, van Mourik R, Maras A, Oosterlaan Rescorla LA, Ewing G, Ivanova MY, Aebi M, Bilenberg N, Dieleman
J: Behavioral effects of neurofeedback compared to stimulants and GC, Dopfner M, Kajokiene I, Leung PW, Pluck J, Steinhausen HC,
physical activity in attention-deficit/hyperactivity disorder: A ran- Winkler Metzke C, Zukauskiene R, Verhulst FC: Parent-adolescent
domized controlled trial. J Clin Psychiatry 77:e1270–e1277, 2016. cross-informant agreement in clinically referred samples: Find-
Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, ings from seven societies. J Clin Child Adolesc Psychol 46:74–87,
Bakken R, Paczkowski M, Kelsey D, Sumner C: Atomoxetine 2017.
treatment for pediatric patients with attention-deficit/hyperactivity Schwartz S, Correll CU: Efficacy and safety of atomoxetine in chil-
disorder with comorbid anxiety disorder. J Am Acad Child Adolesc dren and adolescents with attention-deficit/hyperactivity disorder:
Psychiatry 46:1119–1127, 2007. Results from a comprehensive meta-analysis and metaregression.
Goodman R: The extended version of the Strengths and Difficulties J Am Acad Child Adolesc Psychiatry 53:174–187, 2014.
Questionnaire as a guide to child psychiatric caseness and conse- Shang CY, Gau SS, Soong WT: Association between childhood sleep
quent burden. J Child Psychol Psychiatry 40:791–799, 1999. problems and perinatal factors, parental mental distress and be-
Klimkeit E, Graham C, Lee P, Morling M, Russo D, Tonge B: havioral problems. J Sleep Res 15:63–73, 2006.
Children should be seen and heard: Self-report of feelings and Shang CY, Gau SS: Improving visual memory, attention, and school
behaviors in primary-school-age children with ADHD. J Atten function with atomoxetine in boys with attention-deficit/hyperactivity
Disord 10:181–191, 2006. disorder. J Child Adolesc Psychopharmacol 22:353–363, 2012.
Kratochvil CJ, Heiligenstein JH, Dittmann R, Spencer TJ, Biederman Shang CY, Wu YH, Gau SS, Tseng WY: Disturbed microstructural
J, Wernicke J, Newcorn JH, Casat C, Milton D, Michelson D: integrity of the frontostriatal fiber pathways and executive dys-
Atomoxetine and methylphenidate treatment in children with function in children with attention deficit hyperactivity disorder.
ADHD: A prospective, randomized, open-label trial. J Am Acad Psychol Med 43:1093–1107, 2013.
Child Adolesc Psychiatry 41:776–784, 2002. Shang CY, Pan YL, Lin HY, Huang LW, Gau SS: An open-label,
Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt randomized trial of methylphenidate and atomoxetine treatment in
S, Holman TL, Moser DJ, Paulsen JS: Bupropion SR vs. methyl- children with attention-deficit/hyperactivity disorder. J Child Ado-
phenidate vs. placebo for attention deficit hyperactivity disorder in lesc Psychopharmacol 25:566–573, 2015.
adults. Ann Clin Psychiatry 13:129–134, 2001. Sinzig J, Döpfner M, Lehmkuhl G: Long-acting methylphenidate has
Kutlu A, Akyol Ardic U, Ercan ES: Effect of methylphenidate on an effect on aggressive behavior in children with attention-deficit/
emotional dysregulation in children with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 17:421–
hyperactivity disorder + oppositional defiant disorder/conduct dis- 432, 2007.
order. J Clin Psychopharmacol 37:220–225, 2017. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J,
Lavigne JV, Dulcan MK, LeBailly SA, Binns HJ: Can parent reports Mick E, Aleardi M, Herzig K, Faraone S: A large, double-blind,
serve as a proxy for teacher ratings in medication management of randomized clinical trial of methylphenidate in the treatment of
attention-deficit hyperactivity disorder? J Dev Behav Pediatr 33: adults with attention-deficit/hyperactivity disorder. Biol Psychiatry
336–342, 2012. 57:456–463, 2005.
Lin YJ, Lo KW, Yang LK, Gau SS: Validation of DSM-5 age-of-onset Spencer TJ, Faraone SV, Surman CB, Petty C, Clarke A, Batchelder
criterion of attention deficit/hyperactivity disorder (ADHD) in H, Wozniak J, Biederman J: Toward defining deficient emotional
adults: Comparison of life quality, functional impairment, and self-regulation in children with attention-deficit/hyperactivity dis-
family function. Res Dev Disabil 47:48–60, 2015. order using the Child Behavior Checklist: A controlled study.
Liu SK, Chien YL, Shang CY, Lin CH, Liu YC, Gau SSF: Psycho- Postgrad Med 123:50–59, 2011.
metric properties of the Chinese version of Strength and Difficulties Steinhausen HC, Zulli-Weilenmann N, Brandeis D, Muller UC, Valko
Questionnaire. Compr Psychiatry 54:720–730, 2013. L, Drechsler R: The behavioural profile of children with attention-
Mattos P, Louza MR, Palmini AL, de Oliveira IR, Rocha FL: A deficit/hyperactivity disorder and of their siblings. Eur Child
multicenter, open-label trial to evaluate the quality of life in adults Adolesc Psychiatry 21:157–164, 2012.
with ADHD treated with long-acting methylphenidate (OROS Tseng WL, Gau SS: Executive function as a mediator in the link
MPH): Concerta Quality of Life (CONQoL) study. J Atten Disord between attention-deficit/hyperactivity disorder and social prob-
17:444–448, 2013. lems. J Child Psychol Psychiatry 54:996–1004, 2013.
MEDICATIONS FOR EMOTIONAL/BEHAVIORAL PROBLEMS 11
Volkow ND, Wang GJ, Fowler JS, Ding YS: Imaging the effects of teachers in a Taiwanese nonreferred sample. J Am Acad Child
methylphenidate on brain dopamine: New model on its therapeutic Adolesc Psychiatry 40:1045–1052, 2001.
actions for attention-deficit/hyperactivity disorder. Biol Psychiatry Yu Q, Teixeira CM, Mahadevia D, Huang Y, Balsam D, Mann JJ,
57:1410–1415, 2005. Gingrich JA, Ansorge MS: Dopamine and serotonin signaling
Wang LJ, Chen CK, Huang YS: Changes in behaviour symptoms of during two sensitive developmental periods differentially impact
patients with attention deficit/hyperactivity disorder during treat- adult aggressive and affective behaviors in mice. Mol Psychiatry
ment: Observation from different informants. Psychiatry Invest 10: 19:688–698, 2014.
1–7, 2013.
Weitkamp K, Romer G, Rosenthal S, Wiegand-Grefe S, Daniels J:
German Screen for Child Anxiety Related Emotional Disorders Address correspondence to:
(SCARED): Reliability, validity, and cross-informant agreement in Chi-Yung Shang, MD, PhD
Downloaded by Wegner Health Science Information Center/ University of South Dakota multisite from www.liebertpub.com at 11/21/18. For personal use only.
a clinical sample. Child Adolesc Psychiatry Ment Health 4:19, Department of Psychiatry
2010. National Taiwan University Hospital
Willcutt EG: The prevalence of DSM-IV attention-deficit/hyperactivity No. 7, Chung-Shan South Road
disorder: A meta-analytic review. Neurotherapeutics 9:490–499, Taipei 10002
2012. Taiwan
Yang HJ, Chen WJ, Soong WT: Rates and patterns of comorbidity of
adolescent behavioral syndromes as reported by parents and E-mail: cyshang@ntu.edu.tw